Where is dihydroergotamine mesylate in the changing landscape of migraine therapy?

Expert Opinion on Pharmacotherapy

Volumn 11, Issue 18, 2010, Pages 3085-3093

  Morren, John A ^a,b   Galvez Jimenez, Nestor ^a,b  

^a Department of Neurology ^*  (United States)

^b DEPARTMENT OF COLORECTAL SURGERY   (United States)

Author keywords

Chronic daily headache; DHE; Dihydroergotamine mesylate; Ergots; Migraine

Indexed keywords

6 N (2 HYDROXYCYCLOPENTYL)ADENOSINE; ACETYLSALICYLIC ACID; ADENOSINE A1 RECEPTOR AGONIST; AMPA RECEPTOR ANTAGONIST; ANALGESIC AGENT; ANTIEMETIC AGENT; ANTIMIGRAINE AGENT; BIBN 4096; CAFFEINE; CALCITONIN GENE RELATED PEPTIDE; CALCITONIN GENE RELATED PEPTIDE RECEPTOR ANTAGONIST; CIS CAPSAICIN; DECAHYDRO 6 [2 (1H TETRAZOL 5 YL)ETHYL] 3 ISOQUINOLINECARBOXYLIC ACID; DIAZEPAM; DIHYDROERGOTAMINE MESILATE; GR 190178; KAINIC ACID RECEPTOR ANTAGONIST; LEVADEX; LNMAH 546C88; METOCLOPRAMIDE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NITRIC OXIDE SYNTHASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PNU 142633; SEROTONIN AGONIST; TELCAGEPANT; TRIPTAN DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANILLOID RECEPTOR 1; VANILLOID RECEPTOR AGONIST;

ABDOMINAL DISCOMFORT; AGEUSIA; ANGINA PECTORIS; BLOOD PRESSURE; BURNING SENSATION; CHRONIC DAILY HEADACHE; CLINICAL PRACTICE; CLINICAL PROTOCOL; CLUSTER HEADACHE; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DRUG APPROVAL; DRUG COST; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDICATION; DRUG INFORMATION; DRUG MECHANISM; DRUG SAFETY; DRUG SELF ADMINISTRATION; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERGOTISM; EVIDENCE BASED MEDICINE; FOOD AND DRUG ADMINISTRATION; HEADACHE; HUMAN; HYPERTENSIVE CRISIS; INJECTION SITE PAIN; INJECTION SITE REACTION; LEG CRAMP; LEG PAIN; LIVER TOXICITY; MENSTRUAL MIGRAINE; MIGRAINE; MIGRAINE WITH AURA; MIGRAINE WITHOUT AURA; MODIFIED RASKIN PROTOCOL; MYALGIA; NAUSEA; NOSE CONGESTION; NOSE IRRITATION; NOSE OBSTRUCTION; NOSE SECRETION; OFF LABEL DRUG USE; OUTPATIENT CARE; POSTMARKETING SURVEILLANCE; PRACTICE GUIDELINE; PRESCRIPTION; REPEATED DRUG DOSE; REVIEW; SEIZURE; SHOULDER PAIN; SIDE EFFECT; SMELLING DISORDER; THORAX PAIN; TREATMENT OUTCOME; VASOSPASM; VOMITING;

ANALGESICS, NON-NARCOTIC; ANIMALS; DIHYDROERGOTAMINE; FEMALE; HUMANS; MALE; MIGRAINE DISORDERS; PATIENT SATISFACTION; PRACTICE GUIDELINES AS TOPIC; QUALITY OF LIFE; RECURRENCE; SEX FACTORS;

EID: 78649288523     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2010.533839     Document Type: Review

References (41)

1. Lipton RB, Stewart WF, Diamond S, et al. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache. 2001;41(7):646-57
2. Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia 2004;24(Suppl 1):9-160
3. Stephen D. Silberstein. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the quality standards subcommittee of the American Academy of Neurology. Neurology 2000;55:754-62
4. Diamond S, Wenzel R. Practical approaches to migraine management. CNS Drugs 2002;16(6):385-403
5. Sheftell FD, Feleppa M, Tepper SJ, et al. Patterns of use of triptans and reasons for switching them in a tertiary care migraine population. Headache 2004;44:661-8
6. Johnson MP, Fernandez F, Colson NJ, Griffiths LR. A pharmacogenomic evaluation of migraine therapy. Expert Opin Pharmacother 2007;8(12):1821-35
7. Lipton RB, Silberstein SD, Saper JR, et al. Why headache treatment fails. Neurology 2003;60(7):1064-70
8. Durham PL, Vause CV. Calcitonin gene-related peptide (CGRP) receptor antagonists in the treatment of migraine. CNS Drugs 2010. [Epub ahead of print]
9. Bigal ME, Krymchantowski AV. Emerging drugs for migraine prophylaxis and treatment. MedGenMed 2006;8(2):31 • Concise review of new antimigraine drugs in development.
10. Tfelt-Hansen PC, Koehler PJ. History of the use of ergotamine and dihydroergotamine in migraine from 1906 and onward. Cephalalgia 2008;28(8):877-86 •• Useful paper that chronicles the experience with ergots and the evolution of their role with the advent of DHE.
11. Saper JR, Silberstein S. Pharmacology of dihydroergotamine and evidence for efficacy and safety in migraine. Headache 2006;46(Suppl 4):S171-81 •• Thorough review of available literature.
12. Silberstein SD, McCrory DC. Ergotamine and dihydroergotamine: history, pharmacology, and efficacy. Headache 2003;43(2):144-66 •• Concise, well-written review of the topic.
13. Masterson CG, Durham PL. DHE repression of ATP-mediated sensitization of trigeminal ganglion neurons. Headache 2010. [Epub ahead of print]
14. Young WB. Appropriate use of ergotamine tartrate and dihydroergotamine in the treatment of migraine: current perspectives. Headache 1997;37(Suppl 1):S42-5
15. Quality Standards Subcommittee of the American Academy of Neurology. Practice parameter: appropriate use of ergotamine tartrate and dihydroergotamine in the treatment of migraine and status migrainosus (summary statement). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 1995;45(3 Pt 1):585-7 •• Provides condensed practical information for the clinician.
16. Raskin NH. Repetitive intravenous dihydroergotamine as therapy for intractable migraine. Neurology 1986;36(7):995-7
17. Silberstein SD, Schulman EA, Hopkins MM. Repetitive intravenous DHE in the treatment of refractory headache. Headache 1990;30(6):334-9
18. Kabbouche MA, Powers SW, Segers A, et al. Inpatient treatment of status migraine with dihydroergotamine in children and adolescents. Headache 2009;49(1):106-9
19. Linder SL. Treatment of childhood headache with dihydroergotamine mesylate. Headache 1994;34(10):578-80
20. Winner P, Dalessio D, Mathew N, et al. Office-based treatment of acute migraine with dihydroergotamine mesylate. Headache 1993;33(9):471-5
21. Schran HF, Tse FLS, Chang C-T. Bioequivalence and safety of subcutaneously and intramuscularly administered dihydroergotamine in healthy volunteers. Curr Ther Res 1994;55:1501-8
22. Becker WJ, Riess CM, Hoag J. Effectiveness of subcutaneous dihydroergotamine by home injection for migraine. Headache 1996;36(3):144-8
23. Gallagher RM. Acute treatment of migraine with dihydroergotamine nasal spray. Dihydroergotamine Working Group. Arch Neurol 1996;53(12):1285-91
24. Ziegler D, Ford R, Kriegler J, et al. Dihydroergotamine nasal spray for the acute treatment of migraine. Neurology 1994;44(3 Pt 1):447-53
25. Efficacy, safety, and tolerability of dihydroergotamine nasal spray as monotherapy in the treatment of acute migraine. Dihydroergotamine Nasal Spray Multicenter Investigators. Headache 1995;35(4):177-84
26. Berde B, Sturmer E. Introduction to the pharmacology of ergot alkaloids and related compounds as a basis of their therapeutic application. In: Berde B, Schild HO, editors. Ergot alkaloids and related compounds. Springer-Verlag, Berlin; 1978. p. 1-28
27. Silberstein SD, Young WB. Safety and efficacy of ergotamine tartrate and dihydroergotamine in the treatment of migraine and status migrainosus. Working Panel of the Headache and Facial Pain Section of the American Academy of Neurology. Neurology 1995;45(3 Pt 1):577-84
28. Griffith RW, Grauwiler J, Hodel C, et al. Toxicological considerations. In: Berde B, Schild HO, editors. Ergot alkaloids and related compounds. Springer-Verlag, Berlin; 1978. p. 805-51
29. Drugs@FDA: Dihydroergotamine mesylate. U. S. Food and Drug Administration. Available from: www.accessdata.fda.gov/scripts/cder/drugsatfda/ index.cfm?fuseaction=Search. Overview&DrugName=DIHYDROERGOTAMINE%20MESYLATE [Last accessed 16 June 2010]
30. Drugs.com: MAP Pharmaceuticals Announces FDA Will Not Require a Second Pivotal Efficacy Study for Levadex NDA Submission. Available from: www.drugs.com/nda/levadex-100111.htmlxzz0pZ8bDuJt [Last accessed 16 June 2010]
31. Cook RO, Shrewsbury SB, Ramadan NM. Reduced adverse event profile of orally inhaled DHE (MAP0004) vs IV DHE: potential mechanism. Headache 2009;49(10):1423-34
32. Shrewsbury SB, Kori SH, Miller SD, et al. Randomized, double-blind, placebo-controlled study of the safety, tolerability and pharmacokinetics of MAP0004 (orally-inhaled DHE) in adult asthmatics. Curr Med Res Opin 2008;24(7):1977-85
33. Shrewsbury SB, Cook RO, Taylor G, et al. Safety and pharmacokinetics of dihydroergotamine mesylate administered via a novel (Tempo) inhaler. Headache 2008;48(3):355-67
34. Sandoz Pharmaceuticals Corp., East Hanover, NJ. Data on file
35. Lipton RB. Ergotamine tartrate and dihydroergotamine mesylate: safety profiles. Headache 1997;37(Suppl 1):S33-41 • Thorough exposition on the safety aspects of DHE.
36. Schurks M, Rist PM, Bigal ME, et al. Migraine and cardiovascular disease: systematic review and meta-analysis. BMJ 2009;339:b3914 • Great study, which has put into perspective safety concerns for baseline cardiovascular risk in migraineurs.
37. Tfelt-Hansen P, Lipton RB. Dihydroergotamine. In: Olesen j, Tfelt-Hansen P, Welch KMA, editors. The headaches. Raven Press, New York; 1993. p. 313-22
38. Mondell B, Giuliano R. A prospective evaluation of intramuscular dihydroergotamine for the control of acute migraine in the office setting: preliminary findings [Abstract]. Headache 1992;32:251-2
39. Winner P, Dalessio D, Mathew N, et al. Concomitant administration of antiemetics is not necessary with intramuscular dihydroergotamine. Am J Emerg Med 1994;12(2):138-41
40. Schurks M. Dihydroergotamine: role in the treatment of migraine. Expert Opin Drug Metab Toxicol 2009;5(9):1141-8
41. Pringsheim T, Howse D. In-patient treatment of chronic daily headache using dihydroergotamine: a long-term follow-up study. Can J Neurol Sci 1998;25(2):146-50